- Published at
- by manilatimes.net
neutral
neutral
News for Syndax Pharmaceuticals, Inc. (SNDX)
- Published at
- by manilatimes.net
neutralneutral- Published at
- by gurufocus.com
negativenegativeSyndax Announces Participation in June Investor Conferences
NEW YORK, May 29, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals ( SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies,- Published at
- by manilatimes.net
neutralneutral- Published at
- by benzinga.com
mixedmixedAgilysys, Amer Sports, X Financial And Other Big Stocks Moving Higher On Tuesday - Amer Sports (NYSE:AS), Agilysys (NASDAQ:AGYS)
U.S. stocks were lower, with the Nasdaq Composite falling more than 50 points on Tuesday. Shares of Agilysys, Inc. AGYS rose sharply during Tuesday's session f...- Published at
- by gurufocus.com
neutralneutralSyndax Announces Data Presentations at EHA 2025 Showcasing Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr)
”“ Revumenib abstracts highlight compelling results in acute leukemia across the frontline and R/R setting and multiple genetic populations, including mNPM1, K- Published at
- by manilatimes.net
neutralneutral- Published at
- by gurufocus.com
neutralneutralSyndax Pharmaceuticals Appoints Dr. Nicholas Botwood as Head of Research and Development and Chief Medical Officer
- Dr. Nicholas Botwood comes to Syndax from BMS and brings 25 years of industry experience leading drug development, R&D strategy and global commercialization o- Published at
- by gurufocus.com
positivepositiveSNDX Appoints New Head of Research and Development | SNDX Stock News
Syndax Pharmaceuticals (SNDX) has appointed Dr. Nicholas Botwood as its new Head of Research and Development and Chief Medical Officer. Dr. Botwood joins the co- Published at
- by gurufocus.com
positivepositiveSynlogic (SNDX) to Attend Meeting Hosted by B. Riley in New York | SNDX Stock News
Synlogic, Inc. (SNDX) is set to participate in a meeting organized by B. Riley in New York on May 19. This engagement forms part of the company's strategy to sh- Published at
- by gurufocus.com
neutralneutralADAR1 Capital Management Issues Open Letter to Keros Therapeutics Stockholders
PR NewswireAUSTIN, Texas, May 8, 2025 Announces Intention to Withhold Votes for Directors Dr. Mary Ann Gray and Dr. Alpna SethAUSTIN, Texas, May 8, 2025 /P- Published at
- by manilatimes.net
neutralneutral- Published at
- by gurufocus.com
neutralneutralSNDX: Scotiabank Raises Price Target on Syndax Pharmaceuticals | SNDX Stock News
On May 6, 2025, Scotiabank's analyst George Farmer issued an update on Syndax Pharmaceuticals (SNDX), maintaining a 'Sector Perform' rating. Notably, the price- Published at
- by gurufocus.com
positivepositiveSyndax Pharmaceuticals (SNDX) Buy Rating Reiterated by Guggenheim | SNDX Stock News
In a recent report dated May 6, 2025, Guggenheim analyst Michael Schmidt has reiterated the Buy rating for Syndax Pharmaceuticals (SNDX). The firm maintains its- Published at
- by gurufocus.com
positivepositiveSyndax Pharmaceuticals Inc (SNDX) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Advances
Revvvi Forge Net Revenue: $20 million in the first full quarter of the launch.Nick Timbo Net Revenue: $13.6 million from the first two months of the joint laun- Published at
- by gurufocus.com
mixedmixedDecoding Syndax Pharmaceuticals Inc (SNDX): A Strategic SWOT Insight
Exploring the robust pipeline and commercial strategies of Syndax Pharmaceuticals Inc (SNDX).Delving into the financial intricacies and growth trajectory of SN- Published at
- by gurufocus.com
positivepositiveQ1 2025 Syndax Pharmaceuticals Inc Earnings Call Transcript
May 05, 2025 / 08:30PM GMTOperator Good day, everyone, and welcome to the Syndax first-quarter 2025 earnings conference call. Today's call is being recorded. (O- Published at
- by gurufocus.com
positivepositiveSNDX Reports Strong Revenue and Cash Position, Focuses on Growth
Syndax Pharmaceuticals reports robust revenue growth, indicating strong market entry. Analysts predict significant upside potential for the stock over t- Published at
- by seekingalpha.com
neutralneutralSyndax Pharmaceuticals, Inc. 2025 Q1 - Results - Earnings Call Presentation (NASDAQ:SNDX)
The following slide deck was published by Syndax Pharmaceuticals, Inc.- Published at
- by seekingalpha.com
positivepositiveSyndax Pharmaceuticals, Inc. (SNDX) Q1 2025 Earnings Call Transcript
Call Start: 16:30 January 1, 0000 5:24 PM ETSyndax Pharmaceuticals, Inc.